RHO-TARGET-1

1 study on RHO-TARGET-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on RHO-TARGET-1. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

RHO-TARGET-1 studies and clinical research

2026-04-16 PubMed · in vitro · n preclinical

Macrocyclic Peptides Discovered to Specifically Target Cancer-Associated RhoA Mutation

This research represents a significant advancement by identifying a novel class of macrocyclic peptides that specifically target the oncogenic RhoA G17V mutation. The high specificity and potent in vitro inhibitory ac…

Research tools

Free, no account — handy when you're working with RHO-TARGET-1.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$12 monthly or $33 lifetime

Create free account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

RHO-TARGET-1 studies and clinical research

Macrocyclic Peptides Discovered to Specifically Target Cancer-Associated RhoA Mutation

Research tools